The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EW | +19.46% | +4.15% | +0.82% | +6,102% |
| S&P | +16.53% | +80.89% | +12.59% | +347% |
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
The Motley Fool analyzed 16 billionaire-led hedge funds to get an idea of their healthcare sector investment strategies.
Investors trade on potential rather than trailing results, and they found the company's top-line guidance wanting.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.57B | 13.3% |
| Gross Profit | $1.23B | 13.2% |
| Gross Margin | 78.61% | 0.0% |
| Market Cap | $49.47B | 13.3% |
| Market Cap / Employee | $3.09M | 0.0% |
| Employees | 16K | 1.3% |
| Net Income | $64.20M | -81.4% |
| EBITDA | $420.20M | 7.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.94B | -3.6% |
| Accounts Receivable | $659.60M | 8.3% |
| Inventory | 1.1K | 3.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $680.90M | 0.6% |
| Short Term Debt | $24.50M | 4.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 7.93% | -4.8% |
| Return On Invested Capital | 18.44% | -2.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $353.50M | 299.4% |
| Operating Free Cash Flow | $450.90M | 453.6% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 48.43 | 53.39 | 33.11 | 47.20 | -7.06% |
| Price to Book | 4.27 | 4.53 | 4.34 | 4.85 | 6.05% |
| Price to Sales | 7.69 | 8.09 | 7.74 | 8.17 | 7.04% |
| Price to Tangible Book Value | 6.06 | 6.39 | 6.02 | 6.78 | 8.39% |
| Price to Free Cash Flow TTM | 67.29 | 78.21 | 56.64 | 37.15 | -75.36% |
| Enterprise Value to EBITDA | 90.46 | 93.17 | 89.79 | 109.66 | 6.13% |
| Free Cash Flow Yield | 1.5% | 1.3% | 1.8% | 2.7% | 305.88% |
| Return on Equity | 16.7% | 15.7% | 13.6% | 10.4% | -39.28% |
| Total Debt | $699.40M | $702.60M | $700.30M | $705.40M | 0.77% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
